| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2007;116:2535-2543.)
© 2007 American Heart Association, Inc.
Arrhythmia/Electrophysiology |
From the Leon H. Charney Division of Cardiology (D.M.S., C.Y., G.I.F., G.E.M.), New York University School of Medicine, New York, NY; Department of Cell Biology and Molecular Medicine (V.G.), Cardiovascular Research Institute, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark; Cell and Developmental Biology Program (J.B.E.B.), Fox Chase Cancer Center, Philadelphia, Pa; National Institute of Environmental Health Sciences (Y.M.), Mason, Ohio; and Center for Cardiovascular Development (M.D.S.), Baylor College of Medicine, Houston, Tex.
Correspondence to Gregory E. Morley, New York University School of Medicine, Smilow Research Center, 8th Floor, 522 First Ave, New York, NY 10016. E-mail Gregory.Morley{at}nyumc.org
Received February 21, 2007; accepted August 31, 2007.
| Abstract |
|---|
|
|
|---|
Methods and Results— High-resolution optical mapping with correlative histological analysis of 28 mutant hearts revealed 4 basic phenotypic classes based on electrical activation patterns and volume-conducted ECGs. The frequency of AV node conduction and morphological abnormalities increased from no detectable anomalies (class I) to severe defects (class IV), which included the presence of bypass tracts, abnormal ventricular activation patterns, fibrosis of the AV node, and twin AV nodes.
Conclusion— The present findings demonstrate that bone morphogenetic protein signaling is required in the myocardium of the AV canal for proper AV junction development, including the AV node.
Key Words: atrioventricular node genes electrophysiology
| Introduction |
|---|
|
|
|---|
Editorial p 2520
Clinical Perspective p 2543
Bone morphogenetic proteins (BMPs) are multifunctional signaling molecules expressed throughout development in a multitude of tissues, including the AV canal.9 They are involved in such processes as cell proliferation, migration, differentiation, and apoptosis (reviewed in Chen et al10). In particular, BMP2 is expressed in the myocardium of the AV canal in E11 to E12 mouse embryos.11 Germline knockout of the type 1a BMP receptor, Alk3, leads to embryonic death before gastrulation.12 Cardiomyocyte-specific deletion of Alk3 was lethal to the embryo at mid gestation.13 Mutant hearts exhibited abnormalities in trabeculation, formation of the compact layer and interventricular septum, and endocardial cushion formation. To study the role of BMP signaling specifically in the AV canal, Gaussin et al14 conditionally inactivated Alk3 in the AV canal myocardium by expressing Cre recombinase under the transcriptional control of a chicken GATA-6 (cGATA6) enhancer. These studies demonstrated a requirement for BMP signaling in AV valve development and in formation of the annulus fibrosus. In cGATA6-Cre/Alk3 mice, the posterior tricuspid valve was displaced downward, and disruption of the annulus fibrosus led to the formation of accessory conduction pathways in a portion of mutants, a constellation of findings reminiscent of Ebsteins anomaly.14 To test the hypothesis that BMP signaling in AV myocardium is also critical for the development of the AV node, we analyzed the structure and function of the AV node in cGATA6-Cre/Alk3 mice using a combination of high-resolution optical mapping and correlative histology.
| Methods |
|---|
|
|
|---|
ECGs and Optical Mapping
Surface ECGs were performed under anesthesia as described previously.16 The methods used to optically map the mouse heart have been described previously.17 Briefly, hearts were isolated and perfused by the Langendorff method with warm (37°C), oxygenated (95% O2, 5% CO2) Tyrodes solution. The Tyrodes solution contained (in mmol/L) NaCl 114, NaHCO3 25, dextrose 10, KCl 4.6, CaCl2 1.5, Na2PO4 1.2, and MgCl2 0.7. Once the heart rate stabilized, it was stained with a bolus of the voltage-sensitive dye Di-4-ANEPPs (8 µL of a 2-mmol/L stock solution dissolved in DMSO). The heart was stimulated with a platinum electrode, and volume-conducted ECGs (vECGs) were recorded with Ag-AgCl electrodes placed near the heart. We defined breakthroughs as points on the cardiac surface at which the impulse could be seen radiating out in all directions.
Drug Treatments
Drugs were added to warm Tyrodes solution and perfused through the heart continuously. Initial adenosine treatments ranged from 20 to 80 µmol/L and continued at increasing doses until AV block or asystole was observed. Procainamide treatments began at 45 µg/mL and continued at increasing dosages until AV conduction was restored or asystole was induced.
Histology
After optical mapping, hearts were perfused with KCl 50 mmol/L followed by 10% neutral-buffered formalin. They were further fixed by immersion in 10% neutral-buffered formalin, embedded in paraffin, and sectioned at 6-µm intervals. Staining with Massons trichrome (Poly Scientific, Bay Shore, NY) was performed according to the manufacturers protocol.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
| Results |
|---|
|
|
|---|
|
Class I: Normal Activation Patterns and Nodal Morphology
We studied a total of 28 mutant hearts. Of these, 9 hearts displayed activation patterns that were indistinguishable from controls (Figure 2). vECGs in these class I mutants showed similar PR intervals compared with control mice (not shown). The hearts of 3 class I mutants were processed for histological analysis of the AV node. Sections were stained with Massons trichrome to visualize fibrous tissue in blue. In control hearts, the AV node was a clearly discernible compact structure isolated from the chamber myocardium by fibrous tissue (Figure 3A through 3D). No morphological anomalies were detected in the AV nodes of any of the 3 class I mutant hearts analyzed (Figure 3E and 3F).
|
|
Class II: Intermittent Bypass Conduction
The second group of mutant mice was identified during the optical mapping studies. These cGATA6-Cre/Alk3 mice had normal surface ECGs, but the isolated hearts showed evidence of a bypass tract (Figure 4A and 4B). This behavior was observed in 6 of 28 mice studied. As observed clinically in individuals with ventricular preexcitation,18 impulse conduction in this class of mutants switched between AV nodal conduction and bypass pathways (Figure 4C through 4E). Shorts runs of preferential conduction over accessory pathways could be detected by vECG, but impulse propagation in the mutant hearts was primarily through the AV node. In the majority of class II cGATA6-Cre/Alk3 mice (5 of 6), AV impulses from the apex and accessory impulses from the base were seen to collide on the posterior epicardial surface (Figure 4D), although the vECG was normal at the time (Figure 4D). These findings suggest that AV conduction was preserved, but accessory conduction pathways were also present. Histology data supported this notion, because sections through 2 class II cGATA6-Cre/Alk3 hearts revealed no detectable difference in AV node morphology compared with controls (Figure 3G and 3H).
|
Class III: Primary Bypass Conduction
AV conduction in class III animals occurred exclusively or predominantly through accessory pathways associated with short PR intervals (mean interval 10±2 ms, n=7). Mice with this behavior were recognized previously14 and accounted for 7 of 28 animals in the present study. The PR interval in this class was greatly abbreviated or not present, and a delta wave was observed (Figure 5A). The impulse in class III mutant hearts was observed by optical mapping to travel from the base to the apex of the ventricle (Figure 5C). Such a pattern was never seen in control hearts. Six class III hearts were treated with the type 1A antiarrhythmic agent procainamide. In 1 heart, treatment was able to block conduction over the bypass track and restored AV nodal conduction (Figure 5B and 5D).19 Gross morphological examination of this heart revealed a clear external connection between the coronary sinus and the ventricle (Figure 5E and 5F). The remaining 5 treated hearts exhibited either AV block or bypass, and normal AV conduction was never restored (n=5; Figure 5G and 5H). These data suggest that AV nodal conduction in these hearts was severely compromised. In agreement with this interpretation, histological examination of 4 class III hearts demonstrated obvious AV nodal defects (n=3). Two hearts exhibited fibrosis within the AV node. The fibrosis pushed apart the nodal cells, slightly altering the morphology and likely impairing the ability of impulses to propagate through the node (Figure 6A and 6B). Fibrosis was never detected in control AV nodes (Figure 3A through 3D). The morphology of the third node was extremely disrupted. Rather than a compact, ovoid structure as observed in control hearts (Figure 3A through 3D), the node appeared as a twisted, Y-shaped structure (Figure 6C and 6D).
|
|
Class IV: Severe AV Dysfunction
Class IV mutants had the most atypical activation patterns (n=6 of 28). In contrast to control hearts (Figure 7A), class IV mutant activation maps showed breakthroughs along the anterior septal surface rather than the apex (Figure 7C and 7E). These mutants had either normal (n=2) or prolonged PR intervals measured from vECGs (mean interval 54±1 ms; n=4), which indicates that the impulse was conducted through the node (Figure 7B, 7D, and 7F). In support of the notion that conduction was nodal and not through a slow-conducting bypass tract, adenosine treatment of the majority of mutant hearts led to block (n=4 of 5) at the same concentrations (10 to 40 µmol/L) as in controls. To test whether an abnormal activation pattern would arise from a defect in the ventricular muscle itself, conduction velocities were calculated from maps generated during pacing of the left ventricle and showed no significant difference between mutant and control hearts (data not shown). The entire study was conducted with mice aged 12 to 23 months. Interestingly, no evidence existed of increased-age–related abnormal activation pattern or heart block in control or mutant mice.
|
Histological analysis revealed that all class IV mutant hearts had AV node abnormalities (n=3 of 3; Figure 8). In 1 class IV cGATA3-Cre/Alk3 heart, the AV node appeared stretched and with a loose morphology (Figure 8A and 8B) relative to control (Figure 3A through 3D). The other 2 class IV mutant hearts had twin AV nodes (Figure 8C through 8F). Intriguingly, 1 of these hearts had a relatively normal PR interval, whereas the other showed first-degree block.
|
| Discussion |
|---|
|
|
|---|
For this, cGATA6-Cre/Alk3 mice were analyzed with a combination of high-resolution optical mapping of cardiac impulse propagation, vECG, and correlative histological analysis. We identified a broad range of defects in AV conduction and associated abnormalities in AV nodal structure in these mutant mice. We defined 4 phenotypic classes of mutants in which the frequency of AV node conduction and morphological abnormalities increased from no detectable defects (class I) to severe defects (class IV).
Class I mutant hearts were indistinguishable from control hearts. Class II mutants were defined by the presence but intermittent use of accessory conduction pathways. In these hearts, impulses traveled through the AV node the majority of the time, and AV node morphology appeared normal. In contrast, class III cGATA6-Cre/Alk3 hearts rarely if ever conducted impulses through the AV node, even with procainamide treatment. The preference for bypass versus AV nodal conduction suggested a possible defect in the AV node itself. Histological data confirmed AV node anomalies in 3 of 4 class III hearts, including fibrosis within the node itself and abnormal node shape. Class IV mutants were the most striking, with extremely abnormal activation patterns and no evidence of a bypass tract as determined by AV conduction times. All class IV hearts exhibited AV node abnormalities. In particular, sections from 2 class IV hearts revealed twin AV nodes.
The age of mice used in the present study ranged from 12 to 23 months, and no correlation was detected between age and severity of defect. Surface ECG data, albeit limited in number, indicated that mice that fell into class III showed exclusive bypass conduction when sampled at multiple time points beginning as early as 2 months of age. Thus, currently, no evidence exists that the defects were progressive. Rather, it is very likely that the extent and/or location of Cre recombination during development was the determining factor in the extent of AV conduction dysfunction.15 This suggests that BMP signaling in AV myocardium is not required for maintenance of the AV node function in the adult but rather for proper development of the AV junction.
BMP Signaling in AV Canal Development
The different phenotypes in the 4 classes of mutants identified by optical mapping could have different developmental origins. The cGATA6 enhancer used in the present study is active in 2 posterior and lateral regions of the heart field at E7.5 through E8.5 and becomes restricted to the AV canal myocardium at E9.5.15 Lineage, anatomic, and expression studies have shown the AV myocardium contributes to the AV valves, AV node, His bundle, and the myocardium adjacent to the annulus fibrosus.1,14,15,20 Thus, the development of a number of structures could be affected by alterations in BMP signaling in the AV canal. Studies from chick embryos have revealed that early in development, myocytes of the AV canal dissociate, and the resulting space is filled with extracellular matrix. This coincides with the detection of slow AV conduction through the canal.21–23 If tight cellular connections were maintained between even a portion of AV myocytes, it could lead to the accessory pathways observed in class II and III hearts in the present study. Formation of the AV node and the His bundle occurs as the endocardial cushions fuse, the central fibrous body forms, and ventricular septation is complete, with only 1 pathway left for impulse conduction. In class IV hearts, AV conduction was perturbed without the presence of a bypass tract. The impulse breakthrough in these hearts occurred on the anterior septal surface, which suggests a disruption within the central conduction system of the node, bundle, and bundle branches. One possibility is that BMP signaling is required to maintain proper continuity between the AV node and His bundle or the His bundle and the bundle branches. No cGATA6-Cre–mediated recombination has been detected in the bundle branches or Purkinje fibers.15 Alternatively, disrupted BMP signaling could affect patterning of the AV canal, thereby impacting formation of the entire central conduction system.24–28 Detailed analysis of conduction system morphology and function during development may assist in resolving the origin of these AV defects in cGATA6-Cre mice.
Clinical Significance
Inherited cardiac conduction system defects, although rare, still pose a serious health risk for those afflicted. The abnormalities seen in cGATA6-Cre/Alk3 mice resemble those seen in human disorders such as Ebsteins anomaly and AV conduction disease.29,30 Both of these conditions in patients have been associated with mutations in the BMP target Nkx2.5.30–32 This suggests that BMP signaling through the Alk3 receptor and other downstream components may play a role in congenital conduction system defects. Furthermore, understanding the mechanisms of both normal and ectopic fibrous deposition in the heart is of great interest. Interruption of conduction system tissue by fibrosis is the most common cause of complete heart block.33 The cGATA6-Cre/Alk3 mouse provides a new avenue for investigation into congenital heart defects and underscores the importance of BMP signaling in AV canal myocardium for proper formation of the mature AV junction.
| Acknowledgments |
|---|
Sources of Funding
This work was supported by grants from the National Institutes of Health (HL76751 to Dr Morley, HL69020 and HL59139 to Dr Stephen F. Vatner), a National Research Service Award Fellowship (HL79796 to Dr Stroud), a grant from the American Heart Association (0555840T to Dr Gaussin), and the March of Dimes Birth Defects Foundation (1-FY06-375 to Dr Gaussin).
Disclosures
None.
| References |
|---|
|
|
|---|
2. Viragh S, Challice CE. The development of the conduction system in the mouse embryo heart, II: histogenesis of the atrioventricular node and bundle. Dev Biol. 1977; 56: 397–411.[CrossRef][Medline] [Order article via Infotrieve]
3. Viragh S, Challice CE. The development of the conduction system in the mouse embryo heart, I: the first embryonic A-V conduction pathway. Dev Biol. 1977; 56: 382–396.[CrossRef][Medline] [Order article via Infotrieve]
4. Kondo RP, Anderson RH, Kupershmidt S, Roden DM, Evans SM. Development of the cardiac conduction system as delineated by minK-lacZ. J Cardiovasc Electrophysiol. 2003; 14: 383–391.[CrossRef][Medline] [Order article via Infotrieve]
5. Rentschler S, Vaidya DM, Tamaddon H, Degenhardt K, Sassoon D, Morley GE, Jalife J, Fishman GI. Visualization and functional characterization of the developing murine cardiac conduction system. Development. 2001; 128: 1785–1792.[Abstract]
6. Viragh S, Challice CE. The development of the conduction system in the mouse embryo heart, IV: differentiation of the atrioventricular conduction system. Dev Biol. 1982; 89: 25–40.[CrossRef][Medline] [Order article via Infotrieve]
7. Armstrong EJ, Bischoff J. Heart valve development: endothelial cell signaling and differentiation. Circ Res. 2004; 95: 459–470.
8. Efimov IR, Nikolski VP, Rothenberg R, Greener ID, Li J, Dobrzynski H, Boyett M. Structure-function relationship in the AV junction. Anat Rec A Discov Mol Cell Evol Biol. 2004; 280: 952–965.[CrossRef][Medline] [Order article via Infotrieve]
9. Euler-Taimor G, Heger J. The complex pattern of SMAD signaling in the cardiovascular system. Cardiovasc Res. 2006; 69: 15–25.
10. Chen D, Zhao M, Mundy GR. Bone morphogenetic proteins. Growth Factors. 2004; 22: 233–241.[CrossRef][Medline] [Order article via Infotrieve]
11. Eltyeb A, David R, Lauri JP, Eero J. Overlapping and differential localization of Bmp-2, Bmp-4, Msx-2 and apoptosis in the endocardial cushion and adjacent tissues of the developing mouse heart. Cell Tissue Res. 2001; 305: 67–78.[CrossRef][Medline] [Order article via Infotrieve]
12. Mishina Y, Suzuki A, Ueno N, Behringer RR. Bmpr encodes a type I bone morphogenetic protein receptor that is essential for gastrulation during mouse embryogenesis. Genes Dev. 1995; 9: 3027–3037.
13. Gaussin V, Van de Putte T, Mishina Y, Hanks MC, Zwijsen A, Huylebroeck D, Behringer RR, Schneider MD. Endocardial cushion and myocardial defects after cardiac myocyte-specific conditional deletion of the bone morphogenetic protein receptor ALK3. Proc Natl Acad Sci U S A. 2002; 99: 2878–2883.
14. Gaussin V, Morley GE, Cox L, Zwijsen A, Vance KM, Emile L, Tian Y, Liu J, Hong C, Myers D, Conway SJ, Depre C, Mishina Y, Behringer RR, Hanks MC, Schneider MD, Huylebroeck D, Fishman GI, Burch JBE, Vatner SF. Alk3/Bmpr1a receptor is required for development of the atrioventricular canal into valves and annulus fibrosus. Circ Res. 2005; 97: 219–226.
15. Davis DL, Edwards AV, Juraszek AL, Phelps A, Wessels A, Burch JBE. A GATA-6 gene heart-region-specific enhancer provides a novel means to mark and probe a discrete component of the mouse cardiac conduction system. Mech Dev. 2001; 108: 105–119.[CrossRef][Medline] [Order article via Infotrieve]
16. Gutstein DE, Danik SB, Lewitton S, France D, Liu F, Chen FL, Zhang J, Ghodsi N, Morley GE, Fishman GI. Focal gap junction uncoupling and spontaneous ventricular ectopy. Am J Physiol Heart Circ Physiol. 2005; 289: H1091–H1098.
17. Tamaddon HS, Vaidya D, Simon AM, Paul DL, Jalife J, Morley GE. High-resolution optical mapping of the right bundle branch in connexin40 knockout mice reveals slow conduction in the specialized conduction system. Circ Res. 2000; 87: 929–936.
18. Yee R, Klein GJ, Prystowsky E, Zipes DP, Jalife J. The Wolff-Parkinson-White syndrome and related variants. In: Cardiac Electrophysiology: From Cell to Bedside. Vol 3. Philadelphia, Pa: Saunders; 2006: 845–861.
19. Patel VV, Arad M, Moskowitz IPG, Maguire CT, Branco D, Seidman JG, Seidman CE, Berul CI. Electrophysiologic characterization and postnatal development of ventricular pre-excitation in a mouse model of cardiac hypertrophy and Wolff-Parkinson-White syndrome. J Am Coll Cardiol. 2003; 42: 942–951.
20. Kim JS, Viragh S, Moorman AFM, Anderson RH, Lamers WH. Development of the myocardium of the atrioventricular canal and the vestibular spine in the human heart. Circ Res. 2001; 88: 395–402.
21. Arrechedera H, Strauss M, Arguello C, Ayesta C, Anselmi G. Ultrastructural study of the myocardial wall of the atrio-ventricular canal during the development of the embryonic chick heart. J Mol Cell Cardiol. 1984; 16: 885–895.[CrossRef][Medline] [Order article via Infotrieve]
22. Arguello C, Alanis J, Pantoja O, Valenzuela B. Electrophysiological and ultrastructural study of the atrioventricular canal during the development of the chick embryo. J Mol Cell Cardiol. 1986; 18: 499–510.[CrossRef][Medline] [Order article via Infotrieve]
23. Martinsen BJ. Reference guide to the stages of chick heart embryology. Dev Dyn. 2005; 233: 1317–1327.
24. Yamada M, Revelli JP, Eichele G, Barron M, Schwartz RJ. Expression of chick Tbx-2, Tbx-3, and Tbx-5 genes during early heart development: evidence for BMP2 induction of Tbx2. Dev Biol. 2000; 228: 95–105.[CrossRef][Medline] [Order article via Infotrieve]
25. Christoffels VM, Burch JBE, Moorman AFM. Architectural plan for the heart: early patterning and delineation of the chambers and the nodes. Trends Cardiovasc Med. 2004; 14: 301–307.[CrossRef][Medline] [Order article via Infotrieve]
26. Christoffels VM, Hoogaars WMH, Tessari A, Clout DE, Campione M. T-box transcription factor Tbx2 represses differentiation and formation of the cardiac chambers. Dev Dyn. 2004; 229: 763–770.[CrossRef][Medline] [Order article via Infotrieve]
27. Hoogaars WMH, Tessari A, Moorman AFM, de Boer PAJ, Hagoort J, Soufan AT, Campione M, Christoffels VM. The transcriptional repressor Tbx3 delineates the developing central conduction system of the heart. Cardiovasc Res. 2004; 62: 489–499.
28. Rutenberg JB, Fischer A, Jia H, Gessler M, Zhong TP, Mercola M. Developmental patterning of the cardiac atrioventricular canal by Notch and Hairy-related transcription factors. Development. 2006; 133: 4381–4390.
29. Wolf CM, Berul CI. Inherited conduction system abnormalities: one group of diseases, many genes. J Cardiovasc Electrophysiol. 2006; 17: 446–455.[CrossRef][Medline] [Order article via Infotrieve]
30. Benson DW. Genetics of atrioventricular conduction disease in humans. Anat Rec A Discov Mol Cell Evol Biol. 2004; 280: 934–939.[CrossRef][Medline] [Order article via Infotrieve]
31. Ikeda Y, Hiroi Y, Hosoda T, Utsunomiya T, Matsuo S, Ito T, Inoue J, Sumiyoshi T, Takano H, Nagai R, Komuro I. Novel point mutation in the cardiac transcription factor CSX/NKX2.5 associated with congenital heart disease. Circ J. 2002; 66: 561–563.[CrossRef][Medline] [Order article via Infotrieve]
32. Jay PY, Harris BS, Maguire CT, Buerger A, Wakimoto H, Tanaka M, Kupershmidt S, Roden DM, Schultheiss TM, OBrien TX, Gourdie RG, Berul CI, Izumo S. Nkx2–5 mutation causes anatomic hypoplasia of the cardiac conduction system. J Clin Invest. 2004; 113: 1130–1137.[CrossRef][Medline] [Order article via Infotrieve]
33. Suarez-Penaranda JM, Munoz JI, Rodriguez-Calvo MS, Ortiz-Rey JA, Concheiro L. The pathology of the heart conduction system in congenital heart block. J Clin Forensic Med. 2006; 13: 341–343.[CrossRef][Medline] [Order article via Infotrieve]
| Footnotes |
|---|
This article has been cited by other articles:
![]() |
N. V. Munshi, J. McAnally, S. Bezprozvannaya, J. M. Berry, J. A. Richardson, J. A. Hill, and E. N. Olson Cx30.2 enhancer analysis identifies Gata4 as a novel regulator of atrioventricular delay Development, August 1, 2009; 136(15): 2665 - 2674. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Horsthuis, H. P.J. Buermans, J. F. Brons, A. O. Verkerk, M. L. Bakker, V. Wakker, D. E.W. Clout, A. F.M. Moorman, P. A.C. 't Hoen, and V. M. Christoffels Gene Expression Profiling of the Forming Atrioventricular Node Using a Novel Tbx3-Based Node-Specific Transgenic Reporter Circ. Res., July 2, 2009; 105(1): 61 - 69. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. M. Christoffels and A. F.M. Moorman Development of the Cardiac Conduction System: Why Are Some Regions of the Heart More Arrhythmogenic Than Others? Circ Arrhythm Electrophysiol, April 1, 2009; 2(2): 195 - 207. [Full Text] [PDF] |
||||
![]() |
R.H. Anderson, M.R. Boyett, H. Dobrzynski, J. Yanni, V.M. Christoffels, and A.F.M. Moorman Letter by Anderson et al Regarding Article, "Abnormal Conduction and Morphology in the Atrioventricular Node of Mice With Atrioventricular Canal-Targeted Deletion of Alk3/Bmpr1a Receptor" Circulation, August 5, 2008; 118(6): e105 - e105. [Full Text] [PDF] |
||||
![]() |
R. G. Gourdie and D. Sedmera Letter by Gourdie and Sedmera Regarding Article, "Abnormal Conduction and Morphology in the Atrioventricular Node of Mice With Atrioventricular Canal-Targeted Deletion of Alk3/Bmpr1a Receptor" Circulation, August 5, 2008; 118(6): e106 - e106. [Full Text] [PDF] |
||||
![]() |
D. M. Stroud, C. Yu, G. I. Fishman, G. E. Morley, V. Gaussin, J. B.E. Burch, Y. Mishina, and M. D. Schneider Response to Letters Regarding Article, "Abnormal Conduction and Morphology in the Atrioventricular Node of Mice with Atrioventricular Canal Targeted Deletion of Alk3/Bmpr1a Receptor" Circulation, August 5, 2008; 118(6): e107 - e107. [Full Text] [PDF] |
||||
![]() |
M. L. Bakker, B. J. Boukens, M. T.M. Mommersteeg, J. F. Brons, V. Wakker, A. F.M. Moorman, and V. M. Christoffels Transcription Factor Tbx3 Is Required for the Specification of the Atrioventricular Conduction System Circ. Res., June 6, 2008; 102(11): 1340 - 1349. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Y. Jay Genetic Wiring Diagram of the Cardiac Conduction System Circulation, November 27, 2007; 116(22): 2520 - 2522. [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2007 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |